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Subjective quality of life (SQoL) has been increasingly studied in first-episode psychosis (FEP). Prior research pri-
marily examined the impact of psychiatric symptoms on SQoL. Relationship between treatment-related factors
and SQoL is under-studied. In this study, 159 Chinese patients who had completed 2-year treatment from early
intervention service in Hong Kong were recruited. Assessments on premorbid adjustment, clinical profiles includ-
ing social anxiety measure, functioning, antipsychotic-induced extrapyramidal side-effects and attitude toward
medication treatment were conducted. SQoL was evaluated by Chinese version SF36 which generated mental and
physical component summary (MCS and PCS) scores for analysis. Our results showed that more severe positive
symptoms, higher level of depression, greater social anxiety, more negative attitude toward antipsychotic med-
ications and greater degree of akathisia independently predicted lower MCS score. Higher social anxiety level
and poorer functioning predicted lower PCS score. Our results indicate that affective and positive symptoms,
functioning, and treatment-related variables are critical determinants of SQoL in FEP patients. These identified
factors thus represent potentially malleable therapeutic targets for early detection and prompt intervention to
promote enhancement of SQoL in the early stage of illness.
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1. Introduction
Subjective quality of life (SQoL) has been regarded as an important
outcome dimension in schizophrenia and related psychoses (Malla and
Payne, 2005; Eack and Newhill, 2007). Although there is a lack of con-
sensus definition, SQoL is generally conceptualized as a multi-dimen-
sional construct which refers to an individual's perceived satisfaction
with various life domains encompassing physical health, mental wellbe-
ing and social functioning (Lehman, 1996; World Health Organization,
1998). It is acknowledged that one of the most fundamental features un-
derlying SQoL construct is its subjective nature which provides an av-
enue to understand patients’ life circumstances through their own per-
spectives (Lehman, 1996). Literature has indicated that schizophrenia
is associated with reduced SQoL. A wide array of factors have been
found to influence patients’ self-appraisal of life satisfaction such as
symptomatology, functional disability, different phases of illness, treat-
ment characteristics and socio-cultural values, to name a few (Lehman,
1996; Karow et al., 2014). Accumulating evidence has shown that
SQoL predicts symptomatic remission, relapse
and functional outcome in schizophrenia (Lambert et al., 2007; Boyer et
al., 2013a). Recent data has further suggested potential clinical utility of
integrating SQoL assessment with feedback in routine psychiatric care
for schizophrenia patients to enhance patient-clinician communication
and their service satisfaction (Boyer et al., 2013b).
Recently, an increasing number of research has been conducted to
examine SQoL in patients with first-episode psychosis (FEP) who were
found to have lower levels of satisfaction across most SQoL domains
than the general population (Law et al., 2005). Depression has consis-
tently been found to be a robust predictor of SQoL in first-episode pop-
ulations (Malla et al., 2004; Sim et al., 2004; Law et al., 2005; Melle
et al., 2005, 2010; Wegener et al., 2005; Cotton et al., 2010; Renwick
et al., 2012; Gardsjord et al., 2016). Discrepant findings, however, were
observed with respect to the relationships between other clinical vari-
ables and SQoL in FEP, with some studies showing premorbid adjust-
ment (Malla et al., 2004; Melle et al., 2005; MacBeth et al., 2015), du-
ration of untreated psychosis (DUP) (Malla et al., 2004; Melle et al.,
2005; Gorna et al., 2008), positive symptoms (Gorna et al., 2008; Chee,
2010; Cotton et al., 2010), negative symptoms (Malla et al., 2004;
Gorna et al., 2008; Cotton et al., 2010; Thorup et al., 2010) and func
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tioning (Cotton et al., 2010; Melle et al., 2010; Renwick et al., 2015) as
independent factors associated with SQoL, but not others.
Of note, the majority of previous first-episode studies assessed pa-
tients at initial presentation during which they exhibited active psy-
chotic symptoms that may obscure the potential relationships of SQoL
with various symptom dimensions. It is also possible that predictors of
SQoL may vary at different phases of illness (Bow-Thomas et al., 1999).
Thus far, most prior FEP research primarily examined the impact of psy-
chiatric symptoms on SQoL. There is a paucity of data in FEP regard-
ing the relationship between SQoL and treatment-related variables in-
cluding antipsychotic-induced extrapyramidal side-effects and attitude
toward medications which were found to predict lower SQoL in chronic
samples (Awad et al., 1997; Browne et al., 1998; Hofer et al., 2004).
Although literature demonstrated that anxiety symptoms (Huppert and
Smith, 2001; Braga et al., 2005), especially social anxiety (Pallanti et al.,
2004; Kumazaki et al., 2012) which is the most prevalent comorbid anx-
iety condition in patients with psychotic disorders (Achim et al., 2011),
were related to poorer SQoL in chronic schizophrenia, very few stud-
ies have been conducted to investigate the association between anxiety
symptoms (and none for social anxiety) and SQoL in FEP. Further, most
of these first-episode studies assessed anxiety symptoms by using either
ratings of a single item (Theodore et al., 2012) or a symptom compo-
nent score combining depression and anxiety items (Priebe et al., 2000;
Melle et al., 2005; Gorna et al., 2008; MacBeth et al., 2015) selected
from a general psychopathology scale. Such measurement lacks speci-
ficity to detect the influence of anxiety symptoms, in particular social
anxiety, on SQoL.
Hong Kong (HK) is among the few cities in Asia to implement a ter-
ritory-wide early intervention (EI) service for psychosis. The interven-
tion program Early Assessment Service for Young People with Psychosis
(EASY) was launched in 2001 and comprises three key elements includ-
ing community-awareness programs, open referral system, and 2-year
specialized intervention for young people presenting with FEP (Tang et
al., 2010). We have previously examined the relationships of SQoL with
clinical parameters in FEP patients at first presentation to EASY pro-
gram, with depression being found to be the only variable correlating
with SQoL (Law et al., 2005). In the current report, we sought to iden-
tify the determinants of SQoL in a representative cohort of Chinese FEP
patients upon completion of 2-year treatment from EASY program. Com-
prehensive evaluation of depression, social anxiety, medication side-ef-
fects and attitude toward antipsychotic treatment, alongside standard
measures of premorbid adjustment, psychopathology and functioning
was conducted to enable a better delineation of prediction profiles for
SQoL.
2. Methods
2.1. Participants and setting
Details of the study methodology have been reported elsewhere
(Chang et al., 2015a). Briefly, the current analysis was based on data
obtained from baseline assessment of a single-blind randomized con-
trolled trial (RCT) comparing a 1-year extension of specialized EI (i.e.,
a 3-year EI service) with step-down care (i.e., a 2-year EI service) in
patients who had received 2 years of treatment from EASY program.
This publicly-funded specialized program provides early assessment and
phase-specific intervention for all individuals aged 15–25 years experi-
encing their FEP in HK (Tang et al., 2010). The service consisted of five
clinical teams, each covering a geographically-defined catchment area
and comprising two psychiatrists, three case managers and one social
worker. The service adopts phase-specific case-management approach
in which each patient is assigned with a case manager who provides
protocol-based psychosocial interventions (So, 2013). Patients are as-
sertively followed up for a period of 2 years, after which they are man
aged by step-down clinic in the third year of treatment without provi-
sion of case-management. They are then transferred to generic psychi-
atric service for continuous care.
A total of 160 consecutive patients with a DSM-IV diagnosis of psy-
chotic disorder were recruited from the outpatient units of EASY pro-
gram between November 2010 and August 2011, randomly allocated to
extended EI (Extended EI) or step-down care (SC), and followed up for
12 months. Exclusion criteria were intellectual disability, substance-in-
duced psychosis or psychotic disorder due to general medical condition.
In Extended EI condition, specialized EI was continued in the form of
an additional year of case-management which was closely aligned with
treatment protocols adopted by EASY program. Participants allocated to
SC condition received outpatient medical follow-up with limited com-
munity support which focused mainly on crisis intervention, and no
case-management was provided. Two treatment groups did not differ
from each other regarding the intensity of medical follow-up by psychia-
trists, prescription of antipsychotic medications, and availability of vari-
ous psychosocial interventions and community-based services (Chang et
al., 2015a).
In this report, we focused on investigating clinical, functional and
treatment correlates of SQoL at study intake (i.e., upon completion of
2-year EASY program and prior to randomization) in 159 participants of
the RCT cohort who were clinically stabilized with treatment and had
completed SQoL assessment. The study was approved by the local insti-
tutional review boards. All participants provided written informed con-
sent. For those aged under 18 years, consent was also obtained from a
parent or guardian.
2.2. Assessments
2.2.1. Diagnostic ascertainment
Diagnosis of each participant was ascertained in consensus meetings
attended by senior psychiatrist and research assistants using all avail-
able information including Chinese-bilingual Structured Clinical Inter-
view for DSM-IV (CB-SCID, So et al., 2003), informant histories and
medical records. Previous validation study showed that CB-SCID yielded
reliable DSM-IV diagnoses in Chinese patients with psychotic disorders
(So et al., 2003).
2.2.2. Premorbid functioning and onset characteristics
Premorbid functioning was measured with the Premorbid Adjust-
ment Scale (PAS, Cannon-Spoor et al., 1982). We divided the PAS mea-
sure into academic and social premorbid functioning as adopted by
previous reports (Larsen et al., 2004; Jeppesen et al., 2008; Chang et
al., 2013) based on the results of prior factor-analytic studies on PAS
which consistently demonstrated two separable domains (i.e., academic
and social domains) in patients with psychotic disorders (Allen et al.,
2001; MacBeth and Gumley, 2008). An overall score for each of the
two premorbid functional domains was computed by averaging the rat-
ings for the relevant subscales across developmental stages (score range
0–1, higher score indicates lower functioning). Interview for the Retro-
spective Assessment of the Onset of Schizophrenia (IRAOS, Hafner et al.,
1992) was employed to determine age at onset of psychosis and DUP
which was defined as the time interval between the onset of positive
psychotic symptoms and treatment initiation.
2.2.3. Symptom severity and functioning
Psychopathology was assessed using Positive and Negative Syn-
drome Scale (PANSS, Kay et al., 1987), Calgary Depression Scale (CAS,
Addington et al., 1990), and Liebowitz Social Anxiety Scale (LSAS,
Liebowitz, 1987). LSAS was shown to be a reliable instrument assessing
social anxiety in schizophrenia patients (Pallanti et al., 2004). Psychoso-
cial functioning was measured by Social and Occupational Functioning
Assessment Scale (SOFAS, Goldman et al., 1992).
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2.2.4. Medication side-effects and treatment attitude
Antipsychotic-induced extrapyramidal side-effects including Parkin-
sonism features, akathisia and dyskinesia were assessed using Simp-
son-Angus Scale (SAS, Simpson and Angus, 1970), Barnes Akathisia Rat-
ing Scale (BARS, Barnes, 1989) and Abnormal Involuntary Movement
Scale (AIMS, Guy, 1976), respectively. Patients’ attitude toward antipsy-
chotic medications were measured by a self-report 10-item Drug Atti-
tude Inventory (DAI-10, Awad, 1993), with a higher score indicating
more positive attitude.
2.2.5. Subjective quality of life assessment
Subjective health-related QoL was measured using Chinese version
of Medical Outcome Study 36 Item Short Form Health Survey (SF-36,
Ware and Sherbourne, 1992, Lam et al., 1998) which is a self-rated
questionnaire assessing 8 domains including physical functioning, role
limitation due to physical functioning, bodily pain, general health, vital-
ity, social functioning, role limitation due to emotional problems, and
mental health. Score of each domain ranges from 0 to 100, with higher
score indicating better SQoL. SF-36 has been extensively used in clini-
cal populations of physical and mental illnesses including schizophrenia
(Nasrallah et al., 2004; Leese et al., 2008). Literature has shown that
SF-36 is a reliable and valid measure of health-related SQoL for patients
with psychotic disorders (Tunis et al., 1999; Meijer et al., 2002). Chi-
nese version of SF-36 was validated in healthy participants in a popula-
tion-based study (Lam et al., 1998) and has been studied in Chinese FEP
sample in HK (Law et al., 2005). In this study, mental and physical com-
ponent summary (MCS and PCS) scores (McHorney et al., 1993; Lam
et al., 1998; Leese et al., 2008) were computed as primary measures of
SQoL.
Research assistants who received systematic training on the use of
study instruments before participant recruitment and masked to treat-
ment allocation administered all assessments. Videotaped interviews of
10 cases were selected and independently rated by research assistants
for the purpose of inter-rater reliability evaluation. Intra-class corre-
lation coefficients (ICCs) for PANSS general psychopathology, positive
and negative symptom subscales, CDS total score and SOFAS score were
0.92, 0.96, 0.91, 0.89 and 0.93, respectively, indicating good inter-rater
reliability (Chang et al., 2015a).
2.3. Statistical analysis
The primary analysis focused on identifying predictors of SF-36 MCS
and PCS scores. First, associations of SF-36 MCS and PCS scores with
demographics, premorbid adjustment, and clinical, functional and treat-
ment-related variables were examined using Pearson's product-mean
correlation analysis (continuous candidate variables) and independent
t-test (dichotomous candidate variables) as appropriate. Then, those
variables that were found to be significantly related to SF-36 MCS and
PCS scores in the preceding analyses were entered into multiple linear
regression models to determine which factors independently predicted
these two SF-36 QoL measures. All analyses were performed with the
SPSS, version 24.0, and the level of statistical significance was set at
p<0.05.
3. Results
3.1. Characteristics of the sample
Demographics, premorbid adjustment, clinical and treatment-related
characteristics, and functioning of the study sample are summarized
in Table 1. Of 159 participants, 50.9% were male. The mean age of
the sample was 22.9 years (S.D.=3.19) and the median DUP was 13
weeks (mean=36, S.D.=52.5). Diagnoses of the cohort were schizo
Table 1
Demographics, premorbid adjustment, clinical and treatment characteristics of the study
sample.
Variables Mean (S.D.) / N (%)
Demographics
Age at entry 22.87 (3.19)
Male gender 81 (50.94)
Tertiary education level or above 41 (25.79)
Premorbid adjustment ⁠a
PAS social domain score 0.43 (0.43)
PAS academic domain score 0.41 (0.39)
Illness characteristics and allocated treatment
Age at onset of psychosis 20.21 (3.13)
DUP⁠b, weeks 36 (52.50)
Psychiatric diagnosis
Schizophrenia-spectrum disorder ⁠c 131 (82.39)
Affective psychosis ⁠d 15 (9.43)
Other non-affective psychoses ⁠e 13 (8.18)
Symptom severity and functioning
PANSS positive symptom score 9.21 (3.07)
PANSS negative symptom score 11.91 (5.24)
CDS total score 2.87 (3.44)
LSAS social anxiety total score 37.16 (33.50)
SOFAS score 57.67 (13.98)
Antipsychotics & Medication side-effect
Use of SGA 132 (83.0)
CPZ equivalents 303.46 (253.66)
SAS score 2.80 (3.53)
BARS score 1.59 (2.55)
AIMS score 1.54 (2.52)
Subjective quality of life
SF36 mental component summary score 42.93 (11.84)
SF36 physical component summary score 48.66 (8.94)
Abbreviations: AIMS = Abnormal Involuntary Movement Scale; BARS = Barnes Akathisia
Rating Scale; CDS = Calgary Depression Scale; CPZ = Chlorpromazine; DUP = Duration
of untreated psychosis; LSAS = Liebowitz Social Anxiety Scale; PANSS = Positive and
Negative Syndrome Scale; PAS = Premorbid adjustment scale; SAS = Simpson-Angus
Scale; SF-36= Medical Outcome study 36 Item Short Form Health Survey; SGA,
Second-generation antipsychotic; SOFAS = Social and Occupational Functioning
Assessment Scale.
a PAS social domain comprised 3 of the 5 PAS subscales including sociability and
withdrawal, peer relationships, and social-sexual functioning. PAS academic domain
comprised 2 of the 5 PAS subscales including scholastic performance and adaptation to
school (Allen et al., 2001; Chang et al., 2013).
b Median DUP was 13 weeks.
c Schizophrenia-spectrum disorder included schizophrenia (n=98), schizoaffective
disorder (n=5) and schizophreniform disorder (n=28).
d Affective psychosis included bipolar affective disorder with psychotic symptoms
(n=14) and depressive disorder with psychotic symptoms (n=1).
e Other non-affective psychoses included brief psychotic disorder (n=3), delusional
disorder (n=9) and psychosis not otherwise specified (n=1).
phrenia-spectrum disorder (n=131), affective psychosis (n=15) and
other non-affective psychoses (n=14).
3.2. Predictors of SF-36 QoL measures in multivariate models
As shown in Table 2, both SF-36 MCS and PCS scores were sig-
nificantly associated with ratings on key symptom dimensions includ-
ing PANSS positive and negative symptom scores, depression (CDS to-
tal score) and social anxiety levels (LSAS total score), as well as psy-
chosocial functioning (SOFAS score). SF-36 MCS score was also found
to be significantly related to PAS social domain score, age at onset of
psychosis, antipsychotic-induced extrapyramidal side-effects including
Parkinsonism features (SAS score) and akathisia (BARS score), and at-
titude toward antipsychotic medications (DAI-10 score). There were no
significant relationships of SF-36 PCS score with demographics, pre-
morbid adjustment, illness characteristics, and treatment and side-effect
variables.
Multiple regression analysis revealed that positive symptom sever-
ity, depression and social anxiety levels, attitude toward antipsychotic
medications, and degree of akathisia independently predicted SF-36
MCS score, accounting for 47.8% of the variance (Table 3). SF-36 PCS
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Table 2
Relationships of SF36 QoL measures with demographics, premorbid adjustment, clinical
and treatment characteristics.⁠a
Variables of
interest SF36 MCS score SF36 PCS score
r/t P value r/t P value
Demographics
Age at entry, mean
(SD)
0.145 0.067 0.094 0.239
Male gender, n (%) 0.189 0.850 0.573 0.567
Tertiary
educational level
or above, n (%)
−0.747 0.456 −1.270 0.207
Premorbid
adjustment
PAS social domain
score, mean (SD)
−0.194 0.018 −0.052 0.531
PAS academic
domain score,
mean (SD)
−0.117 0.158 −0.080 0.338
Illness
characteristics
Age at onset of
psychosis, mean
(SD)
0.203 0.010 0.087 0.273
Log DUP⁠b, mean
(SD)
−0.113 0.157 −0.001 0.989
Psychiatric
diagnosis ⁠b, n (%)
0.142 0.887 0.884 0.378
Past admission
history, n (%)
0.858 0.392 −0.701 0.484
Symptom severity &
Functioning
PANSS positive
symptom score,
mean (SD)
−0.478 <0.001 −0.223 0.005
PANSS negative
symptom score,
mean (SD)
−0.285 <0.001 −0.205 0.009
CDS total score,
mean (SD)
−0.505 <0.001 −0.196 0.013
LSAS total score,
mean (SD)
−0.484 <0.001 −0.302 <0.001
Good insight ⁠c, n
(%)
−1.022 0.309 −1.181 0.240
SOFAS score,
mean (SD)
0.197 <0.001 0.285 <0.001
Treatment and side-
effect profiles
Use of SGA, n (%) −0.020 0.984 0.005 0.996
DAI-10 score,
mean (SD)
0.276 <0.001 0.154 0.054
SAS score, mean
(SD)
−0.180 0.025 −0.151 0.061
BARS score, mean
(SD)
−0.376 <0.001 −0.097 0.231
AIMS score, mean
(SD)
0.004 0.960 0.000 0.998
Abbreviations: AIMS = Abnormal Involuntary Movement Scale; BARS = Barnes Akathisia
Rating Scale; CDS = Calgary Depression Scale; DAI = Drug Attitude Inventory; DUP =
Duration of untreated psychosis; LSAS = Liebowitz Social Anxiety Scale; MCS = Mental
component summary; PANSS = Positive and Negative Syndrome Scale; PAS = Premorbid
adjustment scale; PCS = Physical component summary; QoL = Quality of life; SAS =
Simpson-Angus Scale; SGA = Second-generation antipsychotic; SF-36= Medical Outcome
study 36 Item Short Form Health Survey; SOFAS = Social and Occupational Functioning
Assessment Scale.
a Pearson's product-mean correlation analyses and independent t-tests were performed
to examine the relationships of SF36 scores with continuous and categorical variables,
respectively.
b DUP was log-transformed due to its skewed distribution.
c Psychiatric diagnosis was categorized into schizophrenia-spectrum disorder (included
schizophrenia, schizoaffective or schizopreniform disorder) and other psychotic disorders
(included bipolar affective disorder with psychotic symptoms, depressive disorder with
psychotic features, brief psychotic disorder, delusional disorder and psychosis not
otherwise specified) for analysis. Good insight was defined as PANSS item G12 rating <4.
Table 3
Final multiple regression model for prediction of SF36 mental component summary
score.⁠a⁠,⁠b.
Variables in the
equation B t P value 95% CI
PANSS positive
symptom score
−1.076 −4.007 <0.001 −1.608
to
−0.545
CDS total score −0.844 −3.444 0.001 −1.328
to
−0.359
LSAS total score −0.122 −3.963 <0.001 −0.183
to
−0.061
DAI-10 score 0.455 2.591 0.011 0.108 –
0.803
BARS score −0.954 −0.204 0.002 −1.547
to
−0.361
Constant 60.175 24.169 <0.001 55.251
–
65.099
Abbreviations: BARS = Barnes Akathisia Rating Scale; CDS = Calgary Depression Scale;
DAI = Drug Attitude Inventory; LSAS = Liebowitz Social Anxiety Scale; PANSS =
Positive and Negative Syndrome Scale;PAS = Premorbid adjustment scale; SAS =
Simpson-Angus Scale; SF36= Medical Outcome study 36 Item Short Form Health Survey;
SOFAS = Social and Occupational Functioning Assessment Scale.
a PAS social domain score, age at onset of psychosis, PANSS negative symptom score,
SOFAS score and SAS score, which were entered into the multiple regression model, were
excluded as predictors of SF36 mental health score after analysis.
b Final Model: adjusted R⁠2 =0.478, F =26.438, p<0.001.
score was predicted by social anxiety and functional levels which ac-
counted for 12.2% of the variance (Table 4).
4. Discussion
The aim of this study was to investigate clinical and treatment-re-
lated determinants of SQoL in Chinese FEP patients who had received
2-year specialized EI service. Consistent with most previous first-episode
studies (Malla et al., 2004; Sim et al., 2004; Melle et al., 2005; Wegener
et al., 2005; Cotton et al., 2010; Renwick et al., 2012; Gardsjord et
al., 2016), the current report showed that depressive symptoms inde-
pendently predicted mental SQoL, thereby further confirming a criti-
cal role of depression in determining subjective mental wellbeing in
FEP patients. This finding also extend our prior work on examining
clinical correlates of SQoL in FEP patients at service intake (Law et
al., 2005), and indicates depression as a robust predictor of SQoL
in both acute and recovery phase of FEP. The current study, to
Table 4
Final multiple regression model for prediction of SF36 physical component summary
score.⁠a⁠,⁠b.
Variables in the
equation B t P value 95% CI
LSAS total score −0.091 −3.385 0.001 −0.145
to
−0.038
SOFAS score 0.138 2.713 0.007 0.038 –
0.239
Constant 60.175 24.169 <0.001 55.251
–
65.099
Abbreviations: CDS = Calgary Depression Scale; LSAS = Liebowitz Social Anxiety Scale;
PANSS = Positive and Negative Syndrome Scale; SF36= Medical Outcome study 36 Item
Short Form Health Survey; SOFAS = Social and Occupational Functioning Assessment
Scale.
a PANSS positive symptom score, PANSS negative symptom score, and CDS total score,
which were entered into the multiple regression model, were excluded as predictors of
SF36 physical health score after analysis.
b Final Model: adjusted R⁠2 =0.122, F =11.551, p<0.001.
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our knowledge, is the first to examine the influence of social anxiety
on SQoL in FEP patients. The results revealed that social anxiety sig-
nificantly contributed to mental and physical SQoL and thus concur
with the literature on chronic schizophrenia showing that patients with
comorbid social anxiety disorder had lower SQoL than those without
social anxiety disorder (Pallanti et al., 2004). One recent study fur-
ther demonstrated that worsening of social anxiety symptoms over 5
years was associated with decreased SQoL in schizophrenia patients
(Kumazaki et al., 2012). In fact, this is in line with previous reviews
regarding the influence of anxiety disorders on SQoL (Mendlowicz and
Stein, 2000; Olatunji et al., 2007) which found that social anxiety disor-
der or even subthreshold social anxiety symptoms negatively impacted
on an individual's functioning independent of sociodemographic and
other clinical variables, resulting in an increased dissatisfaction with
life. Owing to the scarcity of existing data, further research is required
to confirm our findings of unique contribution of social anxiety to SQoL
in FEP patients.
Contrary to many studies (Malla et al., 2004; Melle et al., 2005;
Wegener et al., 2005; Renwick et al., 2012; MacBeth et al., 2015) which
suggested a lack of association between positive symptoms and SQoL in
FEP samples, our result showed that positive symptoms negatively in-
fluenced mental SQoL. Nonetheless, this finding is consistent with sev-
eral first-episode studies (Chee et al., 2010; Cotton et al., 2010; Thorup
et al., 2010) which examined SQoL at clinical stabilization instead of
at initial presentation and revealed that positive symptoms predicted
SQoL. In fact, this is in agreement with previous research which indi-
cated that the association between positive symptoms and SQoL was
stronger when patients were at clinical stabilization than during the
acute phase of psychosis (Bow-Thomas et al., 1999). This finding also
concurs with past studies on Chinese schizophrenia outpatients which
found that positive symptom severity was inversely related to SQoL
(Xiang et al., 2007, 2008). It is postulated that the traditional Chinese
cultural values that emphasize modesty and oppose extremes may lead
to highly negative attitudes of the general public toward positive psy-
chotic symptoms, which are perceived as “unpredictable” and “potential
threats to safety” (Xiang et al., 2010). The stigmatizing attitudes and dis-
crimination experienced by patients with psychotic disorders may neg-
atively impact on their self-esteem and SQoL. Our result that function-
ing predicted physical SQoL is in keeping with results of earlier stud-
ies which showed that impaired global functioning was associated with
various aspects of perceived life satisfaction including physical domain
in FEP patients (Cotton et al., 2010; Melle et al., 2010; Renwick et al.,
2015).
The influence of antipsychotic-induced side-effects and patients’ at-
titude toward medication has, thus far, not been adequately investi-
gated in FEP. Yet, FEP patients perceived negative impact of antipsy-
chotic treatment as one of the major barriers toward recovery (Lam et
al., 2011). Consistent with results of previous studies on chronic schizo-
phrenia (Awad et al., 1997; Browne et al., 1998; Hofer et al., 2004), we
found that antipsychotic-induced akathisia and negative attitude toward
antipsychotic treatment were associated with poorer mental SQoL. This
echoes findings of our prior research on adult-onset FEP which demon-
strated differential relationships of various antipsychotics with SQoL,
with those medications having higher propensity to induce extrapyra-
midal side-effects being related to lower SQoL (Lee et al., 2015). In fact,
akathisia, which is characterized by motor and subjective inner restless-
ness, has been regarded as one of the most distressing antipsychotic-in-
duced movement disorders (Poyurovsky, 2010). It is also acknowledged
that akathisia is a risk factor for suicidal behavior, particularly when it is
coupled with depression and impulsivity. Our finding regarding the ef-
fect of negative treatment attitude is in line with one recent first-episode
study which revealed that patients’ beliefs about treatment control pre-
dicted SQoL (Theodore et al., 2012).
The findings of a lack of significant association between negative
symptoms and SQoL are contrary to some (Malla et al., 2004; Gorna
et al., 2008; Cotton et al., 2010; Thorup et al., 2010), but not all pre-
vious studies which revealed that higher levels of negative symptoms
adversely impacted on SQoL in FEP patients. One possible explanation
for such discrepancy is the variation in negative symptom measurement
across studies. Most of those studies (Malla et al., 2004; Cotton et al.,
2010; Thorup et al., 2010) that found significant associations employed
a Scale for Assessment of Negative Symptoms (SANS, Andreasen, 1982)
which is specifically designed to assess individual sub-domains of nega-
tive symptom construct and thus provides a more refined and sensitive
negative symptom measurement when compared to PANSS (Blanchard
and Cohen, 2006) (as adopted in the current study), enabling the inves-
tigators to detect subtle associations with SQoL. It might also be possible
that the use of two aggregate SQoL scores instead of individual SF36 do-
main scores might mask the potential significant relationships of these
SQoL domains with negative symptoms. Alternatively, mixed findings
were noted regarding the relationship between DUP and SQoL. Some
studies showed that DUP was negatively correlated with SQoL (Malla et
al., 2004; Melle et al., 2005; Gorna et al., 2008). However, consistent
with other previous research (Ho et al., 2000; Law et al., 2005; Thorup
et al., 2010; Cotton et al., 2010; MacBeth et al., 2015), we found no sig-
nificant association between DUP and SQoL in our FEP sample. The null
finding might, on the other hand, be attributed to the comparatively
short DUP (median DUP: 13 weeks) of our cohort which might then ob-
scure the potential negative impact of prolonged untreated psychosis on
SQoL.
Results of the current study have several clinical implications with
regard to SQoL enhancement. First, given that depression and social
anxiety are major determinants of SQoL in FEP patients and are highly
prevalent in the early stage of illness (Voges and Addington, 2005;
Cotton et al., 2012; Chang et al., 2015b), regular and systematic eval-
uation of these affective symptoms should be integrated in EI service
to facilitate early detection and intervention which will in turn pro-
mote patients’ SQoL. Second, treatment for positive symptoms should
be optimized to minimize the risk of emergence of residual symptoms or
psychosis exacerbation which negatively influences SQoL. Third, treat-
ment-related variables also play a crucial role in determining SQoL and
represent modifiable therapeutic targets in FEP. Thus, close monitoring
and prompt management of antipsychotic-induced side-effects should
be provided. Comprehensive psychoeducation on antipsychotic treat-
ment should be offered to patients, particularly in the initial treatment
phase, to properly address their misconception and negative attitude to-
ward medications. Additionally, more intensive psychosocial interven-
tions should be incorporated to EI service to promote early functional
recovery which is linked to better SQoL.
There are several limitations in the study. First, we did not in-
clude measures on service satisfaction, illness coping styles and cog-
nitive functioning which have been suggested as potential predictors
of SQoL in schizophrenia (Ritsner et al., 2003; Wegener et al., 2005;
Petkari and Pietschnig, 2015). Second, SF-36 is a generic SQoL instru-
ment which may not adequately capture SQoL domains that are specifi-
cally relevant to patients with psychotic disorders. Third, the study sam-
ple was recruited from EASY program which provides EI to patients
aged 15–25 years. Hence, our results may not be generalizable to those
with older age of psychosis onset. Fourth, the current analysis focused
on FEP patients at clinical stabilization who exhibited relatively less se-
vere positive symptoms. This limits the comparability of our findings
with those first-episode studies which examined patients upon their ini-
tial presentation with active psychosis. Fifth, although literature has
supported the validity and reliability of self-report measures of patients
with psychotic disorders, the subjective nature of SQoL evaluation may
still be biased by patients’ degrees of symptom severity, insight and cog-
nitive impairment, as well as their willingness to cooperate with the
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assessment. Sixth, the cross-sectional design precluded us from drawing
conclusions about causal relationship between identified correlates and
SQoL measures. Longitudinal research is required to clarify the course
and prospective predictors of SQoL in the early course of psychotic ill-
ness.
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